174 related articles for article (PubMed ID: 17005039)
1. The Mectizan Donation Program - highlights from 2005.
Alleman MM; Twum-Danso NA; Thylefors BI
Filaria J; 2006 Sep; 5():11. PubMed ID: 17005039
[TBL] [Abstract][Full Text] [Related]
2. The Mectizan Donation Program (MDP).
Thylefors B
Ann Trop Med Parasitol; 2008 Sep; 102 Suppl 1():39-44. PubMed ID: 18718154
[TBL] [Abstract][Full Text] [Related]
3. Identifying co-endemic areas for major filarial infections in sub-Saharan Africa: seeking synergies and preventing severe adverse events during mass drug administration campaigns.
Cano J; Basáñez MG; O'Hanlon SJ; Tekle AH; Wanji S; Zouré HG; Rebollo MP; Pullan RL
Parasit Vectors; 2018 Jan; 11(1):70. PubMed ID: 29382363
[TBL] [Abstract][Full Text] [Related]
4. Report of a Scientific Working Group on Serious Adverse Events following Mectizan(R) treatment of onchocerciasis in Loa loa endemic areas.
Scientific Working Group on Serious Adverse Events in Loa Loa endemic areas
Filaria J; 2003 Oct; 2 Suppl 1(Suppl 1):S2. PubMed ID: 14975059
[TBL] [Abstract][Full Text] [Related]
5. The Mectizan Donation Program: 20 years of successful collaboration - a retrospective.
Colatrella B
Ann Trop Med Parasitol; 2008 Sep; 102 Suppl 1():7-11. PubMed ID: 18718147
[TBL] [Abstract][Full Text] [Related]
6. Mectizan as a stimulus for development of novel partnerships: the international organization's perspective.
Etya'alé DE
Ann Trop Med Parasitol; 1998 Apr; 92 Suppl 1():S73-7. PubMed ID: 9861271
[TBL] [Abstract][Full Text] [Related]
7. For as Long as Necessary: Examining 30 years of MSD's Focus on Achieving Elimination of Onchocerciasis and Lymphatic Filariasis.
Gustavsen KM; Colatrella BD; McCoy T
Int Health; 2018 Mar; 10(suppl_1):i3-i6. PubMed ID: 29186497
[TBL] [Abstract][Full Text] [Related]
8. Beyond providing drugs: the Mectizan® donation stimulates new strategies in service delivery and in strengthening health systems.
Hopkins A
Curr Pharm Biotechnol; 2012 May; 13(6):1110-9. PubMed ID: 22039801
[TBL] [Abstract][Full Text] [Related]
9. Programmatic goals and approaches to onchocerciasis.
Richards F; Hopkins D; Cupp E
Lancet; 2000 May; 355(9216):1663-4. PubMed ID: 10905239
[TBL] [Abstract][Full Text] [Related]
10. The Onchocerciasis Elimination Program for the Americas (OEPA).
Sauerbrey M
Ann Trop Med Parasitol; 2008 Sep; 102 Suppl 1():25-9. PubMed ID: 18718151
[TBL] [Abstract][Full Text] [Related]
11. Progress toward elimination of onchocerciasis in the Americas.
Sauerbrey M; Rakers LJ; Richards FO
Int Health; 2018 Mar; 10(suppl_1):i71-i78. PubMed ID: 29471334
[TBL] [Abstract][Full Text] [Related]
12. The Mectizan Donation Programme--a 10-year report.
Dull HB; Meredith SE
Ann Trop Med Parasitol; 1998 Apr; 92 Suppl 1():S69-71. PubMed ID: 9861270
[TBL] [Abstract][Full Text] [Related]
13. GlaxoSmithKline and Merck: private-sector collaboration for the elimination of lymphatic filariasis.
Gustavsen KM; Bradley MH; Wright AL
Ann Trop Med Parasitol; 2009 Oct; 103 Suppl 1():S11-5. PubMed ID: 19843393
[TBL] [Abstract][Full Text] [Related]
14. Control of onchocerciasis.
Boatin BA; Richards FO
Adv Parasitol; 2006; 61():349-94. PubMed ID: 16735169
[TBL] [Abstract][Full Text] [Related]
15. Towards the elimination of onchocerciasis.
Thylefors B; Alleman M
Ann Trop Med Parasitol; 2006 Dec; 100(8):733-46. PubMed ID: 17227651
[TBL] [Abstract][Full Text] [Related]
16. Onchocercal eye disease and the impact of Mectizan treatment.
Abiose A
Ann Trop Med Parasitol; 1998 Apr; 92 Suppl 1():S11-22. PubMed ID: 9861263
[TBL] [Abstract][Full Text] [Related]
17. The Onchocerciasis Control Programme in West Africa (OCP).
Boatin B
Ann Trop Med Parasitol; 2008 Sep; 102 Suppl 1():13-7. PubMed ID: 18718148
[TBL] [Abstract][Full Text] [Related]
18. Mectizan(®) procurement and delivery for onchocerciasis mass drug administration programmes.
Ogoussan KT; Hopkins A
Acta Trop; 2011 Sep; 120 Suppl 1():S173-6. PubMed ID: 20974105
[TBL] [Abstract][Full Text] [Related]
19. Rapid integrated clinical survey to determine prevalence and co-distribution patterns of lymphatic filariasis and onchocerciasis in a
Brito M; Paulo R; Van-Dunem P; Martins A; Unnasch TR; Novak RJ; Jacob B; Stanton MC; Molyneux DH; Kelly-Hope LA
Parasite Epidemiol Control; 2017 Aug; 2(3):71-84. PubMed ID: 29774284
[TBL] [Abstract][Full Text] [Related]
20. Elimination of human onchocerciasis: history of progress and current feasibility using ivermectin (Mectizan(®)) monotherapy.
Cupp EW; Sauerbrey M; Richards F
Acta Trop; 2011 Sep; 120 Suppl 1():S100-8. PubMed ID: 20801094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
